Table 4.
Randomized clinical trials of tafenoquine for PART against vivax malaria
| Trial 1 | Trial 2 | Trial 3 | |
|---|---|---|---|
| Location | Multi-centers in Asia, Africa, and Americas | Multi-centers in Asia, Africa and Americas | Multi-centers in Asia, Africa and Americas |
| Subjects | Adult non-pregnant G6PD-normal residents with acute vivax malaria | Adult non-pregnant G6PD-normal residents with acute vivax malaria | Adult non-pregnant G6PD-normal residents with acute vivax malaria |
| Treatment arms, and numbers of subjectsa | TQ + CQ = 57PQ + CQ = 50Placebo + CQ = 54 | TQ + CQ = 260PQ + CQ = 129Placebo + CQ = 133 | TQ + CQ = 166PQ + CQ = 85 |
| % Recurrence-free after 6 months | TQ + CQ = 89PQ + CQ = 77Placebo + CQ = 38 | TQ + CQ = 62PQ + CQ = 70Placebo + CQ = 28 | TQ + CQ = 73PQ + CQ = 75 |
| Reference | 105 | 106 | 106 |
aTQ, 300 mg single dose tafenoquine; CQ, 1500 mg chloroquine in three daily doses; PQ, 15 mg primaquine daily for 14 days.